Movement Disorders
News
Database of Eye-Tracking Movements Could Aid Diagnosis and Treatment
Wednesday, April 03, 2019—Eye-tracking technology (Brain Health EyeQ; RightEye, Bethesda, MD) that captures data on people’s eye movements has been used to produce a database of 1 billion data po…
Trofinetide Phase 2 Study Shows Safety and Clinically Relevant Improvement for Rett’s Syndrome
Wednesday, March 27, 2019—Positive results from a phase 2 randomized, placebo-controlled clinical trial (NCT02715115) of trofinetide (Acadia Pharmaceuticals, San Diego, CA; Neuren Pharmaceuticals, Melb…
The Importance of Sleep
Logan Schneider, MD
March/April 2019—Sleep has a critical role in brain health and is an essential part of improving neurologic care for all of our patients.
Sleep & Neurodegenerative Disease
Raman K. Malhotra, MD
March/April 2019—Sleep problems are common and treatable in neurodegenerative disorders, and may also be a treatable risk factor and early biomarker.
Movement Disorders Moment: Rapid Eye Movement Sleep Behavior Disorder
Ahmad Alsibai, MD; and Jill M. Giordano Farmer, DO
March/April 2019—This sleep disorder is a strong predictor for the development of synucleinopathies, including Parkinson’s disease, multiple system atrophy, and dementia with Lewy bodies.
First Patient Enrolled in Phase 3 Study of Troriluzole for Spinocerebellar Ataxia
Friday, March 15, 2019—The first patient has been enrolled in a phase 3 study (NCT03701399) of troriluzole (Biohaven, New Haven, CT) to treat spinocerebellar ataxia (SCA). The primary outcome measur…
Motor Function in Persons with REM Sleep Behavior Disorder Predictive of Conversion to Parkinson’s Disease
Tuesday, March 05, 2019—In a large multicenter study of 1,280 patients diagnosed with rapid eye movement (REM) sleep behavior disorder (RBD), published in Brain, patients’ scores on motor …
Verdiperstat, a Potential Treatment for Multiple System Atrophy, Granted Orphan Drug Status
Wednesday, February 20, 2019—The Food and Drug Administration has granted orphan drug status to verdiperstat (BHV-3241; Biohaven Pharmaceutical, New Haven, CT). Verdiperstat is a novel brain-penetrant mye…
